Werbung
Werbung

BCYC

BCYC logo

Bicycle Therapeutics plc - ADR

6.65
USD
Gesponsert
+0.02
+0.29%
09. Jan., 15:59 UTC -5
Geschlossen
exchange

Nach-Markt

6.65

0.00
+0.02%

BCYC Ergebnisberichte

Positives Überraschungsverhältnis

BCYC übertreffen die 12 der letzten 26Schätzungen.

46%

Nächster Bericht

Datum des nächsten Berichts
23. Feb. 2026
Estimate for Q4 25 (Revenue/ EPS)
$7.22M
/
-$0.95
Implizierte Änderung von Q3 25 (Revenue/ EPS)
-38.49%
/
+11.76%
Implizierte Änderung von Q4 24 (Revenue/ EPS)
+94.65%
/
+15.85%

Bicycle Therapeutics plc - ADR earnings per share and revenue

On 30. Okt. 2025, BCYC reported earnings of -0.85 USD per share (EPS) for Q3 25, beating the estimate of -1.09 USD, resulting in a 22.68% surprise. Revenue reached 11.73 million, compared to an expected 7.48 million, with a 56.88% difference. The market reacted with a +7.09% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 16 analysts forecast an EPS of -0.95 USD, with revenue projected to reach 7.22 million USD, implying an increase of 11.76% EPS, and decrease of -38.49% in Revenue from the last quarter.
FAQ
For Q3 2025, Bicycle Therapeutics plc - ADR reported EPS of -$0.85, beating estimates by 22.68%, and revenue of $11.73M, 56.88% above expectations.
The stock price moved up 7.09%, changed from $8.18 before the earnings release to $8.76 the day after.
The next earning report is scheduled for 23. Feb. 2026.
Based on 16 analysts, Bicycle Therapeutics plc - ADR is expected to report EPS of -$0.95 and revenue of $7.22M for Q4 2025.
Scheck FXEmpire's Earnings Calendar for today's list of reporting companies.
Werbung